RNA5SP312

Across TCGA pan-cancer cohorts, RNA5SP312 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RNA5SP312 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNA5SP312 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNA5SP312 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

STAD, KIRC, and PAAD are the cancer types where RNA5SP312 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	II,III,IV	0.475	0.678	.009	54	view →
KIRC	DFS	Tertile	II,III,IV	0.180	0.656	.026	54	view →
PAAD	OS	Tertile	II,III,IV	0.210	0.556	.007	36	view →
LUSC	OS	Tertile	All	0.192	0.729	.002	18	view →
GBM	DFS	Tertile	All	0.061	0.288	<.001	9	view →
LIHC	OS	Tertile	All	0.164	0.704	.032	9	view →
LAML	DFS	Median	All	0.486	0.277	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNA5SP312–STAD (OS)

Open the STAD breakdown →